These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 32289128)

  • 1. Working adeptly to diagnose and treat adult ADHD.
    Brieler JA; Matsunaga A; Gafford J
    J Fam Pract; 2020 Apr; 69(3):145-149. PubMed ID: 32289128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parent-Reported Improvements in Family Functioning in a Randomized Controlled Trial of Lisdexamfetamine for Treatment of Parental Attention-Deficit/Hyperactivity Disorder.
    Babinski DE; Waxmonsky JG; Waschbusch DA; Humphery H; Pelham WE
    J Child Adolesc Psychopharmacol; 2017 Apr; 27(3):250-257. PubMed ID: 27991835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults.
    Castells X; Blanco-Silvente L; Cunill R
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD007813. PubMed ID: 30091808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Lisdexamfetamine dimesylate: a Treatment Option for Children and Adolescents with Attention Deficit/Hyperactivity Disorder in Germany and Across Europe].
    Häge A; Banaschewski T; Dittmann RW
    Fortschr Neurol Psychiatr; 2015 Dec; 83(12):676-85. PubMed ID: 26714249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Updated 2018 NICE guideline on pharmacological treatments for people with ADHD: a critical look.
    Faltinsen E; Zwi M; Castells X; Gluud C; Simonsen E; Storebø OJ
    BMJ Evid Based Med; 2019 Jun; 24(3):99-102. PubMed ID: 30530806
    [No Abstract]   [Full Text] [Related]  

  • 7. A process for developing community consensus regarding the diagnosis and management of attention-deficit/hyperactivity disorder.
    Foy JM; Earls MF
    Pediatrics; 2005 Jan; 115(1):e97-104. PubMed ID: 15629972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Safety and Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD: A Phase IV, 2-Year, Open-Label Study in Europe.
    Coghill DR; Banaschewski T; Nagy P; Otero IH; Soutullo C; Yan B; Caballero B; Zuddas A
    CNS Drugs; 2017 Jul; 31(7):625-638. PubMed ID: 28667569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder who report clinically significant impairment in executive function: results from a randomized, double-blind, placebo-controlled study.
    Adler LA; Dirks B; Deas PF; Raychaudhuri A; Dauphin MR; Lasser RA; Weisler RH
    J Clin Psychiatry; 2013 Jul; 74(7):694-702. PubMed ID: 23945447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional outcomes from a head-to-head, randomized, double-blind trial of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder and an inadequate response to methylphenidate.
    Nagy P; Häge A; Coghill DR; Caballero B; Adeyi B; Anderson CS; Sikirica V; Cardo E
    Eur Child Adolesc Psychiatry; 2016 Feb; 25(2):141-9. PubMed ID: 25999292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of lisdexamfetamine dimesylate for promoting occupational success in adolescents and young adults with attention-deficit/hyperactivity disorder.
    Gordon CT; Fabiano GA; Hulme KF; Sodano SM; Adragna M; Lim R; Stanford S; Janikowski L; Bufalo B; Rodriguez Z; Swiatek D
    Exp Clin Psychopharmacol; 2021 Aug; 29(4):308-318. PubMed ID: 32297783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment With Lisdexamfetamine Dimesylate Improves Self- and Informant-Rated Executive Function Behaviors and Clinician- and Informant-Rated ADHD Symptoms in Adults: Data From a Randomized, Double-Blind, Placebo-Controlled Study.
    Weisler R; Ginsberg L; Dirks B; Deas P; Adeyi B; Adler LA
    J Atten Disord; 2017 Dec; 21(14):1198-1207. PubMed ID: 24464328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treating Attention-Deficit/Hyperactivity Disorder in Severe Intellectual Disability with Lisdexamfetamine: A Case Report.
    Araújo A; Madeira N; Ventura F; Morais S; Coroa M; Macedo A; Areias G; Borges J
    J Clin Psychopharmacol; 2021 Jul-Aug 01; 41(4):490-492. PubMed ID: 34181364
    [No Abstract]   [Full Text] [Related]  

  • 14. [Not Available].
    Rascher W
    Drug Res (Stuttg); 2018 Nov; 68(S 01):S25-S26. PubMed ID: 30453373
    [No Abstract]   [Full Text] [Related]  

  • 15. ADHD and behavioral disorders: Assessment, management, and an update from DSM-5.
    Austerman J
    Cleve Clin J Med; 2015 Nov; 82(11 Suppl 1):S2-7. PubMed ID: 26555810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation and treatment of pediatric ADHD.
    Denisco S; Tiago C; Kravitz C
    Nurse Pract; 2005 Aug; 30(8):14-17, 19-23; quiz 24-5. PubMed ID: 16094198
    [No Abstract]   [Full Text] [Related]  

  • 17. A new amphetamine oral suspension (Adzenys ER) for ADHD.
    Med Lett Drugs Ther; 2018 Jun; 60(1549):e106-e108. PubMed ID: 29913476
    [No Abstract]   [Full Text] [Related]  

  • 18. Management and Treatment of Attention-Deficit/Hyperactivity Disorder on College Campuses.
    Amyx ML; Hastings KB; Reynolds EJ; Weakley JA; Dinkel S; Patzel B
    J Psychosoc Nurs Ment Health Serv; 2015 Nov; 53(11):46-51. PubMed ID: 26535764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attention-deficit hyperactivity disorder (ADHD): does new research support old concepts?
    Furman LM
    J Child Neurol; 2008 Jul; 23(7):775-84. PubMed ID: 18658077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lisdexamfetamine Dimesylate: A Review in Paediatric ADHD.
    Frampton JE
    Drugs; 2018 Jul; 78(10):1025-1036. PubMed ID: 29923015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.